enGene Holdings IncNASDAQ:ENGN
- LAST PRICE9.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots8.3500/ 2
- Ask / Lots9.7000/ 1
- Open / Previous Close9.0500 / 9.0000
- Day Range
- 52 Week Range
- Volume101,260
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENGN |
|---|---|---|
| 09:32 ET | 1338 | 9.35 |
| 09:34 ET | 9620 | 9.025 |
| 09:36 ET | 1980 | 9.04 |
| 09:38 ET | 3653 | 8.7963 |
| 09:39 ET | 5421 | 8.75 |
| 09:41 ET | 300 | 8.7065 |
| 09:45 ET | 700 | 8.56 |
| 09:48 ET | 507 | 8.755 |
| 09:52 ET | 100 | 8.7 |
| 09:59 ET | 200 | 8.75 |
| 10:03 ET | 104 | 8.75 |
| 10:10 ET | 100 | 8.75 |
| 10:48 ET | 100 | 8.98 |
| 10:55 ET | 800 | 8.86 |
| 11:13 ET | 100 | 8.765 |
| 11:22 ET | 100 | 8.765 |
| 12:18 ET | 16467 | 9.4 |
| 12:20 ET | 2009 | 9.52 |
| 12:23 ET | 200 | 9.52 |
| 12:32 ET | 3650 | 9.5 |
| 12:34 ET | 300 | 9.5 |
| 12:38 ET | 200 | 9.5 |
| 12:54 ET | 500 | 9.41 |
| 12:56 ET | 800 | 9.14 |
| 12:57 ET | 500 | 9.2 |
| 12:59 ET | 200 | 9.03 |
| 01:01 ET | 4523 | 9.245 |
| 01:03 ET | 3073 | 8.975 |
| 01:06 ET | 2200 | 8.85 |
| 01:08 ET | 3800 | 9.025 |
| 01:21 ET | 100 | 9.05 |
| 01:24 ET | 1605 | 9.152 |
| 01:26 ET | 1220 | 8.9183 |
| 01:32 ET | 956 | 9.03 |
| 01:35 ET | 6400 | 9.12 |
| 01:50 ET | 1800 | 9 |
| 01:51 ET | 100 | 9 |
| 01:53 ET | 200 | 8.95 |
| 01:55 ET | 100 | 8.95 |
| 02:06 ET | 300 | 8.95 |
| 02:26 ET | 100 | 9 |
| 02:40 ET | 2322 | 8.9148 |
| 02:56 ET | 1902 | 8.91 |
| 03:34 ET | 1295 | 9 |
| 03:38 ET | 100 | 8.94 |
| 03:39 ET | 3168 | 8.94 |
| 03:45 ET | 900 | 8.94 |
| 03:52 ET | 200 | 8.905 |
| 03:54 ET | 647 | 8.965 |
| 03:59 ET | 1785 | 9 |
Jul 24, 2024
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), from 4:05PM ET on Wednesday Jul 24, 2024 by Dow Jones
4:05PM ET on Wednesday Jul 24, 2024 by Dow JonesDJ EnGene Holdings Names Ron Cooper as CEO, from 6:47AM ET on Wednesday Jul 24, 2024 by Dow Jones
6:47AM ET on Wednesday Jul 24, 2024 by Dow JonesenGene Announces Appointment of Ron Cooper as Chief Executive Officer, from 6:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
6:30AM ET on Wednesday Jul 24, 2024 by Dow Jones*DJ EnGene Announces Appointment Of Ron Cooper As Chief Executive Officer >ENGN, from 6:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
6:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
Jul 18, 2024
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors, from 8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
enGene Holdings Inc | 397.5M | -1.9x | --- |
Alto Neuroscience Inc | 389.5M | -7.6x | --- |
Lexeo Therapeutics Inc | 388.4M | -4.2x | --- |
Kyverna Therapeutics Inc | 383.7M | -5.7x | --- |
Lyell Immunopharma Inc | 415.6M | -1.8x | --- |
Nautilus Biotechnology Inc | 360.8M | -5.4x | --- |
Company Information
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
Contact Information
- Headquarters
- 4868 Rue Levy, Suite 220SAINT-LAURENT, QC, Canada H4R 2P1
- Phone
- 514-332-4888
- Fax
- ---
Executives
- Independent Chairman of the Board
- Richard Glickman
- President, Chief Operating Officer
- Alexander Nichols
- Chief Executive Officer, Director
- Jason Hanson
- Chief Financial Officer, Head - Business Development
- Ryan Daws
- Chief Technology Officer
- Anthony Cheung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $397.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4.70 |
Book Value | $3.12 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
